Outcome of RAI131 Therapy in Patients With Differentiated Thyroid Cancer (Low and Intermediate Risk)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-15

Study Completion Date

2026-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Thyroid cancer is a universally relatively rare neoplasm, accounting for nearly 1-5% of all female cancers and less than 2% of male cancers. In spite of this relatively low incidence, it occupies the first rank among the most common endocrinal malignancies, with a consistent male to female ratio of 1: 3 observed in nearly all ethnic groups and geographic areas.

Differentiated thyroid cancer (DTC) is rated as slowly growing disease with a fairly good outcome where the five-year survival rate for localized tumor is 99.8% Total thyroidectomy, the removal of the entire thyroid gland, is the most common surgical approach-especially for tumors larger than 1 cm, multifocal disease, or suspected lymph node involvement. Lobectomy may be considered for small, low-risk tumors (\<1 cm) confined to a single lobe. If lymph node metastasis is evident clinically or radiologically, neck dissection is performed. Postoperative radioactive iodine (RAI) therapy is used to ablate residual tissue or treat recurrent disease, particularly in iodine-avid tumors and intermediate- to high-risk patients. It may not be necessary for small, low-risk tumors. Thyroid hormone suppression therapy with levothyroxine serves both to replace thyroid hormone and suppress TSH, which could stimulate cancer growth. Long-term monitoring includes serial thyroglobulin (Tg) levels (along with anti-Tg antibodies if needed), neck ultrasound, and, in some cases, additional imaging like RAI scans or PET/CT to detect recurrence

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine.

NCT06134830

Thyroid Cancer

NOT_YET_RECRUITING

Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma

NCT06087068

Thyroid Cancer Surgery Recurrence

RECRUITING PHASE2

OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation

NCT00439127

Differentiated Thyroid Carcinoma

COMPLETED

A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

NCT05733013

Thyroid Cancer Thyroid Refractory Thyroid Cancer

RECRUITING

Recurrence in Patients With Differentiated Thyroid Cancer

NCT06154863

Differentiated Thyroid Cancer

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thyroid Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

low risk

patients typically have intrathyroidal papillary or follicular carcinoma, tumors \<4 cm, no lymph node metastasis or only \<5 small-volume (\<0.2 cm) mico metastases, no vascular invasion (for follicular type), no aggressive histologic features, and no local or distant metastases.

neck ultrasound

Intervention Type DEVICE

ultrasound scan

thyroglobulin

Intervention Type DIAGNOSTIC_TEST

blood test

intermediate risk

includes cases with microscopic extrathyroidal extension (ETE), cervical lymph node metastases (especially \>5 nodes or \>0.2 cm), vascular invasion, aggressive histologic variants, or RAI-avid distant metastases

neck ultrasound

Intervention Type DEVICE

ultrasound scan

thyroglobulin

Intervention Type DIAGNOSTIC_TEST

blood test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

neck ultrasound

ultrasound scan

Intervention Type DEVICE

thyroglobulin

blood test

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Pathologically or cytologically proven differentiated thyroid cancer.

* Total thyroidectomy with or without lymph node dissection
* Patient was treated by RAI after surgery
* Male and female patients
* Age \>18 yrs

Exclusion Criteria

* 1\) Patients with undifferentiated thyroid cancer. 2) patients with high risk (distant metastasis) 3)patient with double malignancy 4) medullary thyroid cancer 4) Patient age \< 18 years. 5)patient not treated by surgery or RAI

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes